Every person is different. So why should medication be one-size-fits-all? Our scientists did what some thought impossible - they put a peptide in a pill, creating the world's first FDA-approved GLP-1 pill for weight management. We’re building on 30 years of obesity research and over 100 years of medical breakthroughs. Learn more here: https://lnkd.in/etzdZWSV
Working in a pharmacy, I’ve seen so many people struggle with obesity and all the health problems that come with it, but still avoid treatment because they’re uncomfortable with injectable medications or feel anxious about them. That’s why this breakthrough honestly feels so important. A GLP-1 pill could open the door for many more people to finally get the help they need and benefit from these treatments without the fear or stigma of injections. It’s exciting to see innovation moving in a direction that can make treatment feel more accessible, more acceptable, and ultimately improve so many lives.
Due to the wartime conditions in Iran, transportation, storage, and widespread implementation of pen injectors and auto-injectors can become significantly challenging. In parallel, empty prefilled syringes (PFS) may still face lower acceptance among parts of the patient population and healthcare market. This is exactly where science and pharmaceutical innovation become truly valuable. The choice between vial systems, PFS, pen injectors, or auto-injectors should not be driven solely by technological advancement, but by real-world patient needs, supply chain resilience, usability, safety, cost-effectiveness, and social acceptance. Innovation becomes meaningful when it aligns not only with scientific progress, but also with the clinical, economic, and societal realities patients live through.
The science behind this pill is as remarkable as the pill itself. Getting a GLP-1 molecule to survive the digestive system — which treats it exactly like any other protein — required solving a problem that had defeated researchers for almost 100 years. The solution wasn't just a better drug. It was a molecular escort designed to protect it long enough to be absorbed. That level of complexity, resolved into something a patient swallows once a day, changes who can realistically maintain treatment. And that matters as much as efficacy.
Very interesting development, especially in a South African context. One of the biggest barriers locally is affordability and medical aid coverage. Many South Africans using GLP-1 medications for weight management are paying privately because most medical aids still classify these treatments as non-essential or lifestyle-related. For patients, the injection format can also feel intimidating or inconvenient long term. If oral GLP-1 options can eventually be priced more competitively and become more accessible through medical aid coverage, it could significantly widen access to treatment in South Africa. Accessibility in obesity care matters just as much as innovation.
Really impressive breakthrough. For years, oral delivery of peptides was considered almost impossible because they would simply break down in the stomach before reaching their target. Seeing Novo Nordisk achieve this after decades of research shows how far innovation in pharmaceutical science has come! 👏
A large part of patient adherence and feeling heard involves having a choice and being able to select an individualized option. Having these two options available is remarkable.
Interesting shift in the obesity space. For years, injections dominated the conversation — but an effective GLP-1 pill could dramatically expand access and patient adoption. Convenience and adherence may become just as important as efficacy moving forward.
Developing a stable and bioavailable oral peptide formulation like this is a monumental scientific and manufacturing undertaking, overcoming significant absorption barriers. Such a milestone significantly broadens patient access to GLP-1 therapy, strengthening Novo Nordisk's leadership in metabolic disease management.
As a pharma process engineer, I know firsthand what a monumental technical win oral peptide delivery is. Stabilizing peptides, overcoming bioavailability barriers, and making them viable in a pill has long been one of the industry’s toughest challenges—so seeing the first FDA-approved oral GLP-1 come to life is incredible. What makes this even more meaningful is the patient-centric choice it creates. Giving people the option between pills and injections isn’t just about convenience; it’s about meeting patients where they are, boosting adherence, and ditching the “one-size-fits-all” mindset. This is exactly the kind of innovation that turns lab and manufacturing work into real, life-changing care for people. 🧪❤️
Who prefers injections? If you can do it with a pill why have the plastic canister at all?